重庆莱美药业股份有限公司 2025 年半年度报告全文 1 重庆莱美药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 重庆莱美药业股份有限公司 2025 年半年度报告 2025 年 8 月 公司存在行业政策、药品降价、产品质量安全、技术开发、对外投资等风 险，敬请投资者注意阅读"第三节 管理层讨论与分析"之"十 公司面临的风险 和应对措施"中对公司风险提示的相关内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 2 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 管理层讨论与分析 8 | | 第四节 | 公司治理、环境和社会 23 | | 第五节 | 重要事项 25 | | 第六节 | 股份变动及股东情况 34 | | 第七节 | 债券相关情况 40 | | 第八节 | 财务报告 41 | 公司负责人梁建生、主管会计工作负责人赖文 ...

Group 1 - The stock price of Laimei Pharmaceutical closed at 5.14 yuan on August 7, down 0.15 yuan from the previous trading day, with an opening price of 5.24 yuan, a high of 5.45 yuan, and a low of 5.09 yuan, resulting in an intraday volatility of 6.81% [1] - The trading volume for the day was 803,500 hands, with a transaction amount of 419 million yuan, and a turnover rate of 7.61% [1] - Laimei Pharmaceutical operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of drugs in areas such as anti-infection and specialty therapeutic categories, with a product line that includes anti-infection drugs, digestive system drugs, and respiratory system drugs [1] Group 2 - On August 7, the net outflow of main funds was 24.27 million yuan, accounting for 0.45% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 166 million yuan, representing 3.06% of the circulating market value [1]

Group 1 - The company's stock closed at 5.58 yuan on August 5, down 0.36% from the previous trading day [1] - The trading volume reached 915 million yuan with a total of 1.5753 million hands traded, and the stock experienced a volatility of 10.54% [1] - The company operates in the chemical pharmaceutical industry, focusing on the research, production, and sales of anti-infection drugs and specialized medications [1] Group 2 - The company is registered in Chongqing and has a product line that includes innovative drugs and assisted reproductive technologies [1] - On August 5, there was a net outflow of 53.45 million yuan in main funds, with a cumulative net outflow of 31.66 million yuan over the past five trading days [1] - The stock experienced a rapid decline in the early trading session, with a drop of over 2% within five minutes [1]

（编辑 王雪儿） 证券日报网讯 莱美药业8月4日在互动平台回答投资者提问时表示，公司子公司四川瀛瑞的纳米炭铁混 悬注射液（CNSI-Fe）二期临床进展顺利，正稳步推进临床试验相关工作。关于该产品研发进展情况公 司将严格按照相关规定履行信息披露义务。 ...

Core Insights - The stock price of Lai Mei Pharmaceutical (300006) closed at 5.6 yuan, up 4.67% with a turnover rate of 10.24% and a trading volume of 1.0816 million lots, amounting to 574 million yuan [1] - The company reported a total revenue of 198 million yuan for Q1 2025, representing a year-on-year growth of 9.54%, while the net profit attributable to shareholders decreased by 201.08% to 13.7753 million yuan [1] - Lai Mei Pharmaceutical has made investments in 27 companies and participated in 1,479 bidding projects, holding 207 trademark registrations and 238 patents [2] Financial Performance - Total revenue for Q1 2025: 198 million yuan, up 9.54% year-on-year [1] - Net profit attributable to shareholders: 13.7753 million yuan, down 201.08% year-on-year [1] - Non-recurring net profit: 14.2911 million yuan, down 92.25% year-on-year [1] - Current ratio: 2.459, quick ratio: 2.157, debt-to-asset ratio: 29.09% [1] Company Overview - Lai Mei Pharmaceutical Co., Ltd. was established in 1999 and is located in Chongqing, primarily engaged in the pharmaceutical manufacturing industry [1] - The registered capital of the company is 1.055911205 billion yuan, with paid-in capital of 428.854034 million yuan [1] - The legal representative of the company is Liang Jiansheng [1]

Group 1 - The company holds a 0.75% stake in Replicor through its wholly-owned subsidiary, Laimei Hong Kong [2] - Replicor's hepatitis B drug development project is progressing steadily, and the company will closely monitor the project's subsequent developments [2] - The company will fulfill its information disclosure obligations in accordance with relevant regulations from the Shenzhen Stock Exchange [2]

Group 1 - The company has established a joint investment with AglaeaPharma to set up Guangxi Aglaea, focusing on multi-target small molecule compound drug screening and early disease detection and diagnostic technology development [2] - AglaeaPharma's project platform has developed multiple technology platforms, product pipelines, and a series of products, forming a globally integrated innovative research and development system [2] - The company will continue to monitor the project's progress and fulfill its information disclosure obligations in a timely manner [2]

格隆汇7月30日丨莱美药业(300006.SZ)在互动平台表示，公司目前暂无注射用钙素产品。 （原标题：莱美药业(300006.SZ)：目前暂无注射用钙素产品） ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-035 重庆莱美药业股份有限公司 关于间接控股股东股权结构拟发生变动的提示性公告 本公司、董事会全体成员及相关股东保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广西国控集团为广西国资委的全资子公司，广投集团、广西国控集团和 公司的实际控制人均为广西国资委，本次交易属于间接控股股东的股权结构变动。 截至本公告披露日，公司控股股东仍为广西梧州中恒集团股份有限公司（以下简 称"中恒集团"），公司实际控制人仍为广西国资委，公司的控股股东及实际控 制人均未发生变化。 近日，公司控股股东中恒集团收到间接控股股东广投集团通知，获悉广投集 团股权结构拟发生变动。现将相关情况公告如下： 一、间接控股股东股权结构变动的基本情况 广投集团收到广西国资委的通知，拟将广西国资委持有的广投集团33%股权 无偿划转至广西国控集团。 本次划转完成后，公司控股股东仍为中恒集团，公司实际控制人仍为广西国 资委，广西国控集团将成为广投集团的股东，持有广投集团33%股权，广西国资 委仍为广投集团的控股股东，持有其67%股权。 二、对公司的影响 本次股权结构 ...

证券代码：300006 证券简称：莱美药业 公告编号：2025-034 重庆莱美药业股份有限公司 关于获得药品补充申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，重庆莱美药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的注射用吗替麦考酚酯注射液（规格：0.5g）《药品补充申请批 准通知书》，现将有关事宜公告如下： | 药品名称 | 药品通用名称：注射用吗替麦考酚酯 | | | | --- | --- | --- | --- | | | 英文名/拉丁名：Mycophenolate Mofetil for Injection | | | | 剂型 | 注射剂 | | | | 注册分类 | 化学药品 | | | | 原药品批准文号 | 国药准字 H20059282 | | | | 药品注册标准编号 | YBH18072025 | | | | 包装规格 | 1 瓶/盒 | | | | 规格 | 0.5g | | | | 通知书编号 | 2025B03351 | | | | 申请内容 | 仿制药注射剂一致性评价，其他变更事 ...